Multiplatform molecular test performance in indeterminate thyroid nodules
Open Access
- 7 August 2020
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 48 (12) , 1254-1264
Abstract
Background: Approximately 25% of thyroid nodule fine‐needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery.Methods: We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance.Results: Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%‐99%) and 90% specificity (95% CI,84%‐95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%‐99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%‐86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%‐54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded.Conclusions: Our results emphasize that decisions for surgery should not solely be based on RAS or RAS‐like mutations. MPTX informs management decisions while accounting for these challenges.Keywords
Funding Information
- Interpace Diagnostics
This publication has 45 references indexed in Scilit:
- Impact of Molecular Screening for Point Mutations and Rearrangements in Routine Air-Dried Fine-Needle Aspiration Samples of Thyroid NodulesThyroid®, 2014
- Central Role of RET in Thyroid CancerCold Spring Harbor Perspectives in Biology, 2013
- The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomasOncogene, 2013
- A Prospective Assessment Defining the Limitations of Thyroid Nodule Pathologic EvaluationAnnals of Internal Medicine, 2013
- Highly prevalent TERT promoter mutations in aggressive thyroid cancersEndocrine-Related Cancer, 2013
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA SamplesThe Journal of Clinical Endocrinology & Metabolism, 2011
- Interobserver and Intraobserver Variation Among Experts in the Diagnosis of Thyroid Follicular Lesions With Borderline Nuclear Features of Papillary CarcinomaAmerican Journal of Clinical Pathology, 2008
- RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine TumorsThyroid®, 2005
- Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.The Journal of Clinical Endocrinology & Metabolism, 1996
- Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinomaThe Journal of Clinical Endocrinology & Metabolism, 1996